A clinical report detailing two cases of T/myeloid mixed-phenotype acute leukemia (MPAL-T/M) demonstrates the identification of a recurrent chromosomal translocation, designated t(14;16)(q32;q24), resolved through optical genome mapping (OGM). MPAL-T/M is an uncommon, high-risk hematologic malignancy defined by blasts expressing both T-cell and myeloid lineage markers, where definitive diagnosis requires the synthesis of clinical, immunophenotypic, and comprehensive genetic data. In both evaluated patients, OGM uncovered a shared structural rearrangement between chromosomes 14q32 and 16q24 that was cryptic on initial conventional karyotyping in one case and present as the sole abnormality by OGM in the other, establishing this structural variation as a recurrent event in this ambiguous-lineage subtype.
Genomic characterization of the structural breakpoints placed the chromosome 14 alterations between 500 and 900 kilobases downstream of the 3-prime terminus of the BCL11B gene, while the corresponding partner breakpoints on chromosome 16 localized within or approximately 100 kilobases distal to the long intergenic non-protein coding RNA LINC01081. In both patient samples, the structural configuration resulted in the translocation of the putative BCL11B enhancer, located roughly one megabase downstream of the BCL11B transcription start site, onto the derivative chromosome 16. This physical juxtaposition mirrors the molecular architecture observed in T-cell acute lymphoblastic leukemia (T-ALL) involving BCL11B and TLX3, indicating that the rearrangement may activate a novel oncogenic target on chromosome 16 through enhancer hijacking.
The first clinical case involved a 31-year-old male who initially sought emergency evaluation for suspected gastroenteritis and was found to have marked leukocytosis of 246,000 cells per microliter, anemia with a hemoglobin level of 8.8 grams per deciliter, and thrombocytopenia with a platelet count of 98,000 per microliter. Abdominal and pelvic computed tomography revealed splenomegaly alongside lymphadenopathy, while bone marrow biopsy confirmed a markedly hypercellular marrow containing 26 percent blasts. Flow cytometric analysis detected peripheral and marrow blast populations co-expressing cytoplasmic CD3, TdT, CD13, CD117, and dim CD34, accompanied by immature myeloid cells exhibiting dysplastic neutrophils, an immaturity shift in granulocytes with aberrantly reduced side scatter, and monocytes with decreased HLA-DR expression.
Conventional cytogenetics for the first patient revealed complex karyotypic alterations, including deletions on chromosomes 6q, 9p, and 11q, an unbalanced translocation between chromosomes 4q and 9p causing homozygous deletion of 9p, trisomy 18, and an isochromosome 7q. Chromosomal microarray confirmed homozygous deletions encompassing CDKN2A and CDKN2B at 9p21.3 and a 5.2-megabase loss at 2p16.1p15 affecting BCL11A and REL, alongside a copy-neutral loss of heterozygosity spanning 56.5 megabases on chromosome 11.
Metaphase fluorescence in situ hybridization (FISH) in the first patient demonstrated translocation of both 5-prime and 3-prime BCL11B probes to chromosome 16 in all ten examined metaphase cells, indicating a rearrangement breakpoint centromeric to the 3-prime BCL11B locus. OGM subsequently resolved the cryptic t(14;16)(q32;q24) translocation, placing the chromosome 14 breakpoint approximately 500 kilobases downstream of BCL11B and the chromosome 16 breakpoint within LINC01081. Following induction chemotherapy with a hybrid myeloid-lymphoid regimen and consolidation therapy, the patient received an allogeneic hematopoietic stem cell transplant, achieving morphologic and cytogenetic remission despite persistent minimal residual disease evidenced by flow cytometry and a residual WT1 mutation.
Four months post-transplantation, the first patient developed an ankle mass and systemic hypermetabolic lesions involving the liver, peritoneum, and mediastinal lymph nodes; biopsy confirmed an atypical histiocytic proliferation bordering T-lymphoblasts, consistent with transdifferentiation of the leukemia into histiocytic sarcoma. Genomic profiling of the ankle lesion and marrow revealed persistence of the initial JAK2 and WT1 mutations alongside an acquired NRAS mutation, with BCL11B probe translocation confirmed by FISH. The patient developed recurrent mixed-lineage leukemia in the bone marrow, accompanied by gastrointestinal bleeding, rising leukocytosis, and expanding extramedullary disease, and ultimately expired after transition to supportive care.
The second evaluated patient, a 28-year-old male presenting with nausea, vomiting, diarrhea, generalized lymphadenopathy, and splenomegaly, exhibited a leukocyte count of 208,000 per microliter, hemoglobin of 13.1 grams per deciliter, and a platelet count of 74,000 per microliter. Bone marrow evaluation revealed marked hypercellularity with 21 percent blasts and an abnormal myeloid proliferation. Flow cytometry identified T-lymphoblasts positive for cytoplasmic CD3, CD1a, CD2, CD5, CD7, and dim CD34, alongside a distinct population of abnormal immature monocytic myeloid cells expressing CD11b, CD11c, CD13, CD15, CD33, CD64, and myeloperoxidase, satisfying diagnostic criteria for MPAL-T/M.
Targeted next-generation sequencing in the second patient detected a WT1 frameshift mutation at a 48.5 percent variant allele frequency alongside three distinct activating JAK3 mutations with variant allele frequencies ranging from 19.3 to 28.9 percent, while karyotyping demonstrated gains of chromosomes 6, 7, and 19. OGM performed on peripheral blood detected t(14;16)(q32;q24) as a solitary structural abnormality, mapping the chromosome 14 breakpoint approximately 900 kilobases downstream of BCL11B and the chromosome 16 breakpoint approximately 100 kilobases distal to LINC01081. Both leukemias in this study were consistently negative for FLT3-ITD alterations despite sharing high-frequency pathogenic WT1 mutations and activating JAK-STAT pathway variants.
The second patient attained an initial morphologic and cytogenetic remission after hybrid induction chemotherapy, although flow cytometric monitoring revealed persistent minimal residual T-lymphoblasts that subsequently expanded into dominant relapsed T-lymphoblastic leukemia without a myeloid component. Following conversion to an acute lymphoblastic leukemia salvage protocol and allogeneic stem cell transplantation, the patient experienced rapid central and extramedullary progression within two months, presenting with abdominal pain, altered mental status, cutaneous involvement by T-lymphoblasts, and marrow cellularity replaced by over 90 percent lymphoblasts, leading to clinical deterioration and death under comfort care.
The identification of t(14;16)(q32;q24) highlights both the diagnostic utility and technical scope of optical genome mapping in detecting structural variants and enhancer-hijacking events that evade conventional karyotyping, FISH, and standard sequencing. While the 1-megabase region distal to the chromosome 16 breakpoints contains coding genes such as FOXF1, FOXC2, FOXL1, MTHFSD, and MAP1LC3B alongside several noncoding RNAs, none have previously established causal roles in acute leukemia, underscoring the need for further three-dimensional chromatin conformation and gene expression analyses across larger cohorts to define the target oncogene and the broader therapeutic significance of this recurrent rearrangement.
The characterization of BCL11B alterations situates these findings within an evolving classification framework for ambiguous-lineage leukemias. BCL11B functions as a master regulator of T-lineage commitment, and leukemias harboring BCL11B activation represent an established subtype accounting for up to thirty percent of early T-cell precursor acute lymphoblastic leukemias and mixed-phenotype acute leukemias, alongside fewer than five percent of acute myeloid leukemias. Consequently, recent updates to both the World Health Organization classification and the International Consensus Classification recognize BCL11B-rearranged or BCL11B-activated leukemias as distinct disease entities. In classic BCL11B-activated disease, overexpression typically stems from enhancer hijacking involving the relocation of hematopoietic stem and progenitor cell super-enhancers, such as ARID1B, CDK6, or MYC-BENC, or from the amplification of a 2.5-kilobase region approximately 700 kilobases downstream that acts as a neo-enhancer. Conversely, the structural rearrangements identified in these two cases reflect the reverse mechanism, wherein the downstream BCL11B enhancer itself is translocated to drive an ectopic partner gene, paralleling rearrangements that hijack this regulatory locus to upregulate TLX3, LMO2, NKX2-1, HOXA13, or HOXB13.
The diagnostic resolution achieved here underscores established performance disparities across molecular cytogenetic methodologies. Conventional karyotyping, targeted fluorescence in situ hybridization, and standard high-throughput sequencing panels frequently fail to detect structural rearrangements that reposition intact regulatory elements without producing chimeric gene fusions. In a referenced investigation evaluating 467 acute leukemia specimens, optical genome mapping and RNA sequencing demonstrated an overall concordance rate of only 20.6 percent in identifying enhancer-hijacking events, with transcriptomic sequencing failing to capture all BCL11B structural variants. By evaluating high-molecular-weight genomic DNA molecules of at least 150 kilobases, optical mapping circumvents these diagnostic blind spots and discriminates BCL11B-activation events from BCL11B enhancer-hijacking translocations through high-resolution breakpoint mapping. However, because optical genome mapping is strictly a DNA-based structural assay, it does not measure functional transcription levels directly, necessitating complementary three-dimensional chromatin conformation mapping and expression profiling to confirm downstream target activation.
These molecular insights emerge against a challenging therapeutic backdrop characterized by the absence of universally standardized treatment protocols for mixed-phenotype acute leukemia. For leukemias harboring concurrent signaling aberrations, targeted therapeutic strategies remain under active consideration. Preclinical investigations have documented antileukemic activity using venetoclax combined with the FLT3 inhibitor gilteritinib in BCL11B-activated models, and clinical experience in Philadelphia chromosome-negative lymphoblastic leukemia supports testing JAK inhibitors alongside cytotoxic chemotherapy when JAK-STAT signaling is activated. Nevertheless, because definitive clinical trial data in mixed-phenotype populations are currently lacking, the efficacy of targeted FLT3 and JAK inhibition remains unproven, highlighting the ongoing clinical vulnerability of patients with aggressive, lineage-ambiguous acute leukemias.
Subject of Research: Identification of recurrent t(14;16) translocations and BCL11B enhancer hijacking in T/myeloid mixed-phenotype acute leukemia using optical genome mapping
Article Title: Optical genome mapping reveals a recurrent translocation, t(14;16), in T/myeloid mixed phenotype acute leukemia: report of two cases
Article References: Lum, J., Anderson-Calleja, J., Van Dine, K., Manion, E., Xiao, H., Perry, A. M., Boyer, D., & Shao, L. (2026). Optical genome mapping reveals a recurrent translocation, t(14;16), in T/myeloid mixed phenotype acute leukemia: report of two cases. Molecular Cytogenetics, 19(1), Article 13. https://doi.org/10.1186/s13039-026-00753-8
Image Credits: AI Generated
DOI: 10.1186/s13039-026-00753-8
Keywords: Optical Genome Mapping, Mixed-Phenotype Acute Leukemia, MPAL-T/M, t(14;16) Translocation, BCL11B, Enhancer Hijacking, LINC01081, WT1 Mutation, JAK2 Mutation, JAK3 Mutations, Structural Variants, Flow Cytometry, Histiocytic Sarcoma, Transdifferentiation, Stem Cell Transplantation, Cytogenetics
News Source: Nathaniel Bowman. (November 20, 2026). Optical Genome Mapping Identifies Recurrent Chromosomal Translocation in Mixed Phenotype Leukemia. Scienmag.



